Drug Type Small molecule drug |
Synonyms CBL 137, CBLC-137, CX-137 + [2] |
Mechanism FACT antagonists(SPT16 homolog, facilitates chromatin remodeling subunit antagonists), NF-κB modulators(Nuclear factor NF-kappa-B complex modulators), YAP1 inhibitors(65 kDa Yes-associated protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H25ClN2O2 |
InChIKeyIXRKBBVMDMKAEB-UHFFFAOYSA-N |
CAS Registry1197397-89-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Central Nervous System Neoplasms | Phase 2 | US | 28 Jan 2022 | |
Lymphoma | Phase 2 | US | 28 Jan 2022 | |
Metastatic melanoma | Phase 1 | US | 30 Nov 2022 | |
Melanoma recurrent | Phase 1 | US | 01 Jul 2019 | |
Melanoma, Cutaneous Malignant | Phase 1 | US | 01 Jul 2019 | |
Recurrent Sarcoma of the Extremity | Phase 1 | US | 01 Jul 2019 | |
Sarcoma of the Extremity | Phase 1 | US | 01 Jul 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 Jul 2013 | |
Glioblastoma | Phase 1 | US | 01 Jul 2013 | |
Solid tumor | Phase 1 | RU | 24 Apr 2012 |
NCT01905228 (ASCO2020) Manual | Phase 1 | 83 | viqqywbzdp(ncxgaxhnpt) = okhmzpvsth vntxnhhdol (siihybtqca ) View more | Positive | 29 May 2020 | ||
Phase 1 | 60 | mefexhhjza(iwqqibtsfq) = prolongation of QTc Gr 3, neutropenia/thrombocytopenia Gr 4, LV dysfunction Gr 3 jqqubemyvp (wdwbtowzxb ) View more | Positive | 25 May 2020 |